Brinton Pharmaceuticals, an innovation-driven global pharmaceutical and dermatology company, has appointed Sathya Narayanan as Chief Executive Officer – India Cluster & JPAC (Japan Asia Pacific Cluster).

Narayanan brings more than two decades of leadership experience in pharmaceuticals and dermatology, with expertise in business expansion, growth acceleration, and market leadership. 

Prior to joining Brinton, he served as Managing Director of Galderma South Asia/Emcutix for nearly two decades, where he played a key role in expanding the company’s regional footprint and driving business transformation.

Under his leadership, Galderma India achieved significant milestones through strategic market expansion, the introduction of globally recognised therapies, and initiatives aimed at strengthening dermatology standards through scientific collaborations and medical excellence.

“We are delighted to welcome Sathya Narayanan to Brinton,” said Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals.

“India and neighbouring markets are strategically important growth engines for Brinton, and Sathya’s deep industry expertise, strategic vision, and leadership capabilities make him exceptionally well-positioned to lead our next phase of growth," he added.

Sathya Narayanan has also served on the Executive Committee of the Organization of Pharmaceutical Producers of India and chaired multiple committees focused on medical affairs, regulatory strategy, and legal initiatives.

“Joining Brinton at such an exciting phase of its evolution is truly inspiring,” said Sathya Narayanan. “Brinton has built a strong foundation backed by innovation, scientific excellence, and an ambitious global vision. India and neighbouring markets present immense opportunities for advancing healthcare access and bringing differentiated therapies to patients.”